Acadian Asset Management
AMRX icon

Acadian Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Acadian Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.6M Sell
1,650,255
-281,639
-15% -$3.86M 0.03% 352
2026
Q1 		$24M Sell
1,931,894
-89,277
-4% -$1.2M 0.03% 354
2025
Q4 		$25.5M Sell
2,021,171
-569,351
-22% -$6.51M 0.04% 302
2025
Q3 		$25.9M Sell
2,590,522
-72,002
-3% -$646K 0.05% 282
2025
Q2 		$21.5M Buy
2,662,524
+64,230
+2% +$484K 0.04% 299
2025
Q1 		$21.8M Buy
2,598,294
+880,471
+51% +$7.35M 0.06% 217
2024
Q4 		$13.6M Buy
1,717,823
+546,736
+47% +$4.59M 0.04% 299
2024
Q3 		$9.74M Buy
1,171,087
+359,234
+44% +$2.81M 0.03% 351
2024
Q2 		$5.15M Buy
811,853
+710,598
+702% +$4.51M 0.02% 486
2024
Q1 		$613K Buy
101,255
+11,415
+13% +$64.4K ﹤0.01% 963
2023
Q4 		$545K Buy
+89,840
New +$400K ﹤0.01% 1011
2022
Q4 		– Sell
-7,618
Closed -$15K – 1763
2022
Q3 		$15K Hold
7,618
– – ﹤0.01% 1617
2022
Q2 		$24K Sell
7,618
-52,418
-87% -$190K ﹤0.01% 1594
2022
Q1 		$248K Sell
60,036
-56,410
-48% -$250K ﹤0.01% 1162
2021
Q4 		$556K Buy
116,446
+26,507
+29% +$132K ﹤0.01% 987
2021
Q3 		$478K Sell
89,939
-82,621
-48% -$416K ﹤0.01% 1059
2021
Q2 		$883K Buy
172,560
+93,177
+117% +$530K ﹤0.01% 960
2021
Q1 		$534K Buy
+79,383
New +$440K ﹤0.01% 1168
2020
Q4 		– Sell
-10,914
Closed -$42K – 2188
2020
Q3 		$42K Hold
10,914
– – ﹤0.01% 1900
2020
Q2 		$52K Sell
10,914
-34,086
-76% -$140K ﹤0.01% 1904
2020
Q1 		$157K Hold
45,000
– – ﹤0.01% 1253
2019
Q4 		$217K Hold
45,000
– – ﹤0.01% 1272
2019
Q3 		$131K Hold
45,000
– – ﹤0.01% 1418
2019
Q2 		$323K Buy
45,000
+22,073
+96% +$226K ﹤0.01% 1119
2019
Q1 		$325K Buy
+22,927
New +$303K ﹤0.01% 1227

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Acadian Asset Management's AMRX Position: Q2 2026 in Review

Acadian Asset Management reduced its Amneal Pharmaceuticals (AMRX) stake by 15% in Q2 2026, selling an estimated $3.86M and leaving 1,650,255 shares worth $28.6M. The position accounts for 0.03% of the portfolio, ranked #352.

Acadian Asset Management first reported a position in AMRX in Q1 2019 and has held it in 25 quarters since. 232 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Acadian Asset Management held 1,650,255 shares of Amneal Pharmaceuticals worth $28.6M as of Q2 2026.
  • Acadian Asset Management sold 281,639 Amneal Pharmaceuticals shares in Q2 2026, an estimated $3.86M.
  • Amneal Pharmaceuticals made up 0.03% of Acadian Asset Management's portfolio in Q2 2026, its #352 holding.
  • Acadian Asset Management first reported a position in Amneal Pharmaceuticals in Q1 2019 and has held it in 25 quarters since.
  • 232 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.